Skip to search formSkip to main contentSkip to account menu

FR260330

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Piperidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
New strategy for the antifibrotic therapy with oral administration of FR260330 (a selective inducible nitric oxide synthase inhibitor) in rat experimental liver cirrhosis
Inducible nitric oxide synthase (iNOS) activity is significantly elevated in viral hepatitis, alcoholic cirrhosis, and… 
2006
2006
Effect of a Novel Inducible Nitric Oxide Synthase Inhibitor, FR260330, in Prevention of Renal Ischemia/Reperfusion Injury in Vervet Monkeys
Cytotoxic nitric oxide (NO) is produced during ischemia/reperfusion (I/R) injury by the expression of inducible NO synthase (iNOS… 
2006
2006
FK330, a Novel Inducible Nitric Oxide Synthase Inhibitor, Prevents Ischemia and Reperfusion Injury in Rat Liver Transplantation
Nitric oxide (NO), produced via inducible NO synthase (iNOS), is implicated in the pathophysiology of liver ischemia/reperfusion… 
Highly Cited
2005
Highly Cited
2005
Nuclear Factor-κB Decoy Oligodeoxynucleotides Prevent Acute Lung Injury in Mice with Cecal Ligation and Puncture-Induced Sepsis
The transcription factor nuclear factor-κB (NF-κB) plays a key role in expression of many inflammatory genes responsible for the… 
2005
2005
Pharmacological profile of FR260330, a novel orally active inducible nitric oxide synthase inhibitor.
2005
2005
Effect of a Novel Inducible Nitric Oxide Synthase Inhibitor in Prevention of Rat Chronic Aortic Rejections
Background. Cytotoxic nitric oxide (NO) is produced during ischemia-reperfusion injury and acute and chronic rejection in… 
2005
2005
New strategy for antifibrotic therapy with FR260330 (a selective inducible nitric oxide synthase inhibitor) in rat experimental liver cirrhosis
2004
2004
RENAL ISCHEMIA/REPERFUSION INJURY PREVENTED BY A NOVEL INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITOR, fr260330, IN NONHUMAN PRIMATES
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)